News & Blog

News & Blog

| Aug 25 2026

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia (FORWARD-FA)

| May 3 2025

An Open Label Study of Nomlabofusp in Subjects With Friedreich’s Ataxia

| Mar 19 2024

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects with Friedreich’s Ataxia – CTI-1601